Yuki Tajima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuki Tajima has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Caroline de Courville
Sanofi
1 shared publication Cyril Esnault
Data Science Consulting, Quinten, Paris, France
1 shared publicationDaisuke Koya
Department of Diabetology and Endocrinology, Kanazawa Medical University, Uchinada, Japan
1 shared publicationDian Kang
Data Science Consulting, Quinten, Paris, France
1 shared publication- Fang Liz Zhou
Sanofi Bridgewater New Jersey USA
1 shared publication - Fukao
Sanofi Global Oncology, Cambridge, USA
1 shared publication
Latest Publications
- Open Access
- 2 July 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (8) , 1099-1114
Characterization of Prurigo Nodules in Adults With Moderate‐To‐Severe Atopic Dermatitis in Japan: A 2‐Year Observational Study
Clinical phenotypes of atopic dermatitis (AD) can vary, with some individuals displaying difficult‐to‐treat prurigo nodularis‐like lesions. We aimed to assess the real‐world disease burden and treatment course of Japanese adults with AD‐associated prurigo nodules (AD‐Pn) receiving conventional AD treatments. Of the 300 participants with moderate‐to‐severe AD registered in the observational ADDRESS‐J study between July 29, 2016 and July 4, 2017 (before the first biologic for AD was introduced), 285 had baseline and post‐baseline prurigo assessments and were included in this exploratory analysis (108 with AD‐Pn and 177 without Pn). Participants with AD‐Pn versus those without Pn included more males (73.1% vs. 53.1%), and had more mean ± standard deviation (SD) visits for AD treatment in the previous year (11.5 ± 16.1 vs. 8.7 ± 6.6 visits), a higher proportion with an Investigator's Global Assessment (IGA) 4 score (39.9% vs. 18.6%), a higher mean ± SD Eczema Area and Severity Index (EASI) score (28.4 ± 15.1 vs. 23.5 ± 15.5), and a higher mean ± SD Patient‐Oriented Eczema Measure (POEM) score (18.8 ± 6.2 vs. 15.6 ± 6.8). At baseline, 14.8% and 7.4% of participants with AD‐Pn had been treated with oral immunosuppressants and oral corticosteroids, respectively, compared with 8.5% and 2.3%, respectively, of those without Pn. Individuals with AD‐Pn previously received more intensive topical treatments. At 2 years, participants with AD‐Pn had more severe AD than those without Pn, as assessed by IGA 4 scores (9.1% vs. 0.9%), and higher mean ± SD EASI total scores (12.5 ± 10.7 vs. 7.0 ± 8.1). In summary, individuals with AD‐Pn were mostly males, whose AD was more severe and had improved less than those without Pn while receiving mostly conventional AD treatments over 2 years. AD‐Pn might be an indicator for targeted treatment to improve long‐term AD outcomes. Clinical Trial Registration: ADDRESS‐J (UMIN Clinical Trial Registration: UMIN000022623)
- 2 July 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (8) , 1099-1114
Open AccessCharacterization of Prurigo Nodules in Adults With Moderate‐To‐Severe Atopic Dermatitis in Japan: A 2‐Year Observational Study
Clinical phenotypes of atopic dermatitis (AD) can vary, with some individuals displaying difficult‐to‐treat prurigo nodularis‐like lesions. We aimed to assess the real‐world disease burden and treatment course of Japanese adults with AD‐associated prurigo nodules (AD‐Pn) receiving conventional AD treatments. Of the 300 participants with moderate‐to‐severe AD registered in the observational ADDRESS‐J study between July 29, 2016 and July 4, 2017 (before the first biologic for AD was introduced), 285 had baseline and post‐baseline prurigo assessments and were included in this exploratory analysis (108 with AD‐Pn and 177 without Pn). Participants with AD‐Pn versus those without Pn included more males (73.1% vs. 53.1%), and had more mean ± standard deviation (SD) visits for AD treatment in the previous year (11.5 ± 16.1 vs. 8.7 ± 6.6 visits), a higher proportion with an Investigator's Global Assessment (IGA) 4 score (39.9% vs. 18.6%), a higher mean ± SD Eczema Area and Severity Index (EASI) score (28.4 ± 15.1 vs. 23.5 ± 15.5), and a higher mean ± SD Patient‐Oriented Eczema Measure (POEM) score (18.8 ± 6.2 vs. 15.6 ± 6.8). At baseline, 14.8% and 7.4% of participants with AD‐Pn had been treated with oral immunosuppressants and oral corticosteroids, respectively, compared with 8.5% and 2.3%, respectively, of those without Pn. Individuals with AD‐Pn previously received more intensive topical treatments. At 2 years, participants with AD‐Pn had more severe AD than those without Pn, as assessed by IGA 4 scores (9.1% vs. 0.9%), and higher mean ± SD EASI total scores (12.5 ± 10.7 vs. 7.0 ± 8.1). In summary, individuals with AD‐Pn were mostly males, whose AD was more severe and had improved less than those without Pn while receiving mostly conventional AD treatments over 2 years. AD‐Pn might be an indicator for targeted treatment to improve long‐term AD outcomes. Clinical Trial Registration: ADDRESS‐J (UMIN Clinical Trial Registration: UMIN000022623)
- Open Access
- 12 November 2024
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 18 (11) , e70032
The Burden of Seasonal Influenza and Its Potential Complications Among Older Japanese Adults: A Real‐World Database Study
Background: Seasonal influenza may lead to severe complications, including respiratory and cardiovascular disease, that result in considerable healthcare resource utilization (HCRU) and mortality, particularly in older individuals. This real‐world study assessed the burden of influenza and its potential complications in older Japanese adults.Methods: This retrospective claims database analysis (April 2015 to June 2019) included insured individuals aged ≥ 60 years at the start of four consecutive influenza seasons in Japan (October 1 to April 30). The primary endpoint was the incidence of influenza‐related emergency room (ER) and outpatient visits, the incidence of hospitalizations, the probability of 30‐day inpatient mortality, and 60‐day medical costs of influenza or its potential complications.Results: Of 8,974,708 individuals (43.2% male, mean ± standard deviation age 73.8 ± 8.9 years), 370,430 (4.13%) were diagnosed with influenza. Overall, 17.18 (95% confidence interval [CI] 16.32–18.04) and 3893.53 (3880.87–3906.19) per 100,000 individuals had influenza‐related ER and outpatient visits, respectively, and 181.50 (178.71–184.28) per 100,000 individuals were hospitalized for influenza. The incidence of influenza‐related ER visits and hospitalizations for influenza or potential complications and the probability of 30‐day inpatient mortality increased with age.Conclusions: Seasonal influenza and its potential complications represent a substantial burden that increases with age in Japanese individuals.
- 12 November 2024
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 18 (11) , e70032
Open AccessThe Burden of Seasonal Influenza and Its Potential Complications Among Older Japanese Adults: A Real‐World Database Study
Background: Seasonal influenza may lead to severe complications, including respiratory and cardiovascular disease, that result in considerable healthcare resource utilization (HCRU) and mortality, particularly in older individuals. This real‐world study assessed the burden of influenza and its potential complications in older Japanese adults.Methods: This retrospective claims database analysis (April 2015 to June 2019) included insured individuals aged ≥ 60 years at the start of four consecutive influenza seasons in Japan (October 1 to April 30). The primary endpoint was the incidence of influenza‐related emergency room (ER) and outpatient visits, the incidence of hospitalizations, the probability of 30‐day inpatient mortality, and 60‐day medical costs of influenza or its potential complications.Results: Of 8,974,708 individuals (43.2% male, mean ± standard deviation age 73.8 ± 8.9 years), 370,430 (4.13%) were diagnosed with influenza. Overall, 17.18 (95% confidence interval [CI] 16.32–18.04) and 3893.53 (3880.87–3906.19) per 100,000 individuals had influenza‐related ER and outpatient visits, respectively, and 181.50 (178.71–184.28) per 100,000 individuals were hospitalized for influenza. The incidence of influenza‐related ER visits and hospitalizations for influenza or potential complications and the probability of 30‐day inpatient mortality increased with age.Conclusions: Seasonal influenza and its potential complications represent a substantial burden that increases with age in Japanese individuals.
- Open Access
- 29 April 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-9
Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer
Background: We aimed to evaluate relationships between clinical outcomes and explanatory variables by network clustering analysis using data from a post marketing surveillance (PMS) study of castration-resistant prostate cancer (CRPC) patients. Methods: The PMS was a prospective, multicenter, observational study of patients with metastatic, docetaxel-refractory CRPC treated with cabazitaxel in Japan after its launch in 2014. Graphical Markov (GM) model-based simulations and network clustering in ‘R’ package were conducted to identify correlations between clinical factors and outcomes. Factors shown to be associated with overall survival (OS) in the machine learning analysis were confirmed according to the clinical outcomes observed in the PMS. Results: Among the 660 patients analyzed, median patient age was 70.0 years, and median OS and time-to-treatment failure (TTF) were 319 and 116 days, respectively. In GM-based simulations, factors associated with OS were liver metastases, performance status (PS), TTF, and neutropenia (threshold 0.05), and liver metastases, PS, and TTF (threshold 0.01). Factors associated with TTF were OS and relative dose intensity (threshold 0.05), and OS (threshold 0.01). In network clustering in ‘R’ package, factors associated with OS were number of treatment cycles, discontinuation due to disease progression, and TTF (threshold 0.05), and liver and lung metastases, PS, discontinuation due to adverse events, and febrile neutropenia (threshold 0.01). Kaplan–Meier analysis of patient subgroups demonstrated that visceral metastases and poor PS at baseline were associated with worse OS, while neutropenia or febrile neutropenia and higher number of cabazitaxel cycles were associated with better OS. Conclusions: Neutropenia may be a predictive factor for treatment efficacy in terms of survival. Poor PS and distant metastases to the liver and lungs were shown to be associated with worse outcomes, while factors related to treatment duration were shown to positively correlate with better OS.
- 29 April 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-9
Open AccessComprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer
Background: We aimed to evaluate relationships between clinical outcomes and explanatory variables by network clustering analysis using data from a post marketing surveillance (PMS) study of castration-resistant prostate cancer (CRPC) patients. Methods: The PMS was a prospective, multicenter, observational study of patients with metastatic, docetaxel-refractory CRPC treated with cabazitaxel in Japan after its launch in 2014. Graphical Markov (GM) model-based simulations and network clustering in ‘R’ package were conducted to identify correlations between clinical factors and outcomes. Factors shown to be associated with overall survival (OS) in the machine learning analysis were confirmed according to the clinical outcomes observed in the PMS. Results: Among the 660 patients analyzed, median patient age was 70.0 years, and median OS and time-to-treatment failure (TTF) were 319 and 116 days, respectively. In GM-based simulations, factors associated with OS were liver metastases, performance status (PS), TTF, and neutropenia (threshold 0.05), and liver metastases, PS, and TTF (threshold 0.01). Factors associated with TTF were OS and relative dose intensity (threshold 0.05), and OS (threshold 0.01). In network clustering in ‘R’ package, factors associated with OS were number of treatment cycles, discontinuation due to disease progression, and TTF (threshold 0.05), and liver and lung metastases, PS, discontinuation due to adverse events, and febrile neutropenia (threshold 0.01). Kaplan–Meier analysis of patient subgroups demonstrated that visceral metastases and poor PS at baseline were associated with worse OS, while neutropenia or febrile neutropenia and higher number of cabazitaxel cycles were associated with better OS. Conclusions: Neutropenia may be a predictive factor for treatment efficacy in terms of survival. Poor PS and distant metastases to the liver and lungs were shown to be associated with worse outcomes, while factors related to treatment duration were shown to positively correlate with better OS.
- Open Access
- 3 May 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (8) , 1925-1934
Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium‐glucose co‐transporter‐2 inhibitors with those receiving dipeptidyl peptidase‐4 inhibitors, using a supervised machine‐learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database
Aims: To investigate the effects of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors vs. dipeptidyl peptidase‐4 (DPP‐4) inhibitors on renal function preservation (RFP) using real‐world data of patients with type 2 diabetes in Japan, and to identify which subgroups of patients obtained greater RFP benefits with SGLT2 inhibitors vs. DPP‐4 inhibitors. Methods: We retrospectively analysed claims data recorded in the Medical Data Vision database in Japan of patients with type 2 diabetes (aged ≥18 years) prescribed any SGLT2 inhibitor or any DPP‐4 inhibitor between May 2014 and September 2016 (identification period), in whom estimated glomerular filtration rate (eGFR) was measured at least twice (baseline, up to 6 months before the index date; follow‐up, 9 to 15 months after the index date) with continuous treatment until the follow‐up eGFR. The endpoint was the percentage of patients with RFP, defined as no change or an increase in eGFR from baseline to follow‐up. A proprietary supervised learning algorithm (Q‐Finder; Quinten, Paris, France) was used to identify the profiles of patients with an additional RFP benefit of SGLT2 inhibitors vs. DPP‐4 inhibitors. Results: Data were available for 990 patients prescribed SGLT2 inhibitors and 4257 prescribed DPP‐4 inhibitors. The proportion of patients with RFP was significantly greater in the SGLT2 inhibitor group (odds ratio 1.27; P = 0.01). The Q‐Finder algorithm identified four clinically relevant subgroups showing superior RFP with SGLT2 inhibitors ( P < 0.1): no hyperlipidaemia and eGFR ≥79 mL/min/1.73 m 2 ; eGFR ≥79 mL/min/1.73 m 2 and diabetes duration ≤1.2 years; eGFR ≥75 mL/min/1.73 m 2 and use of antithrombotic agents; and haemoglobin ≤13.4 g/dL and LDL cholesterol ≥95.1 mg/dL. In each profile, glycaemic control was similar in the two groups. Conclusion: SGLT2 inhibitors were associated with more favourable RFP vs. DPP‐4 inhibitors in patients with certain profiles in real‐world settings in Japan.
- 3 May 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (8) , 1925-1934
Open AccessIdentification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium‐glucose co‐transporter‐2 inhibitors with those receiving dipeptidyl peptidase‐4 inhibitors, using a supervised machine‐learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database
Aims: To investigate the effects of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors vs. dipeptidyl peptidase‐4 (DPP‐4) inhibitors on renal function preservation (RFP) using real‐world data of patients with type 2 diabetes in Japan, and to identify which subgroups of patients obtained greater RFP benefits with SGLT2 inhibitors vs. DPP‐4 inhibitors. Methods: We retrospectively analysed claims data recorded in the Medical Data Vision database in Japan of patients with type 2 diabetes (aged ≥18 years) prescribed any SGLT2 inhibitor or any DPP‐4 inhibitor between May 2014 and September 2016 (identification period), in whom estimated glomerular filtration rate (eGFR) was measured at least twice (baseline, up to 6 months before the index date; follow‐up, 9 to 15 months after the index date) with continuous treatment until the follow‐up eGFR. The endpoint was the percentage of patients with RFP, defined as no change or an increase in eGFR from baseline to follow‐up. A proprietary supervised learning algorithm (Q‐Finder; Quinten, Paris, France) was used to identify the profiles of patients with an additional RFP benefit of SGLT2 inhibitors vs. DPP‐4 inhibitors. Results: Data were available for 990 patients prescribed SGLT2 inhibitors and 4257 prescribed DPP‐4 inhibitors. The proportion of patients with RFP was significantly greater in the SGLT2 inhibitor group (odds ratio 1.27; P = 0.01). The Q‐Finder algorithm identified four clinically relevant subgroups showing superior RFP with SGLT2 inhibitors ( P < 0.1): no hyperlipidaemia and eGFR ≥79 mL/min/1.73 m 2 ; eGFR ≥79 mL/min/1.73 m 2 and diabetes duration ≤1.2 years; eGFR ≥75 mL/min/1.73 m 2 and use of antithrombotic agents; and haemoglobin ≤13.4 g/dL and LDL cholesterol ≥95.1 mg/dL. In each profile, glycaemic control was similar in the two groups. Conclusion: SGLT2 inhibitors were associated with more favourable RFP vs. DPP‐4 inhibitors in patients with certain profiles in real‐world settings in Japan.